The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.

A Samsung University team found that mutation load measured with the Guardant360 liquid biopsy assay predicted response as well as tissue-based TMB.

In addition, Qiagen has partnered with Japan's SRL for companion diagnostic development, and its CareHPV test was added to the WHO list of prequalified IVDs.

Myriad said that it will fund the $375 million acquisition with a combination of cash, common stock, and funds from its revolving credit facility.

The group, called GOBLET, has turned its focus to more advanced courses, harmonizing curricula, and reaching out to high schoolers.

The UPenn team will collect genetic information from outside patient cohorts, reorganize it in a streamlined process, and provide a database for downstream studies.

Large-scale population sequencing projects and consumer genomics markets are picking up and oncology continues to be a strong market for Illumina.

Researchers used CRISPR to engineer mice that have multiple genetic variants associated with late-onset AD to facilitate research into biomarkers and treatments.

The firm said it will use the funds to build its IP portfolio, expand its team, and develop an infrastructure for partners to build on its CRISPR platform.

Researchers saw subway line-specific microbes on the hands of subway riders, with increased skin microbial community convergence in samples from evening commuters.

Centrillion Technologies received a multimillion US dollar investment from WeDoctor while Centrillion Technologies Taiwan obtained a strategic investment from Arm IoT Fund.

A number of consumer genetic testing companies are adopting best practice guidelines for customer privacy, the Washington Post reports.

Yale School of Medicine's Michael Murray argues in the Annals of Internal Medicine for making genomic screening routine.

Researchers in Japan being a new trial of induced pluripotent stem cells to treat Parkinson's disease, Science reports.

In PNAS this week: Smyd1 regulates mitochondrial metabolism in the heart, evolutionary history of ASICs, and more.

As part of Myriad Genetics' integration with recently acquired firm Counsyl, the company announced a number of personnel changes. Rishi Kacker, formerly Counsyl's senior VP of technology, will become Myriad's new chief technology officer. Alexander Ford, previously president of Myriad Genetic Laboratories, will be president of the company's women's health business unit, while Eric Evans, Counsyl's chief scientific officer, will now serve as the chief scientific officer of the women's health unit. Lastly, Lloyd Sanders, previously general manager of the oncology segment, will be president of Myriad's oncology business unit.

Agilent Technologies said its senior VP and CFO Didier Hirsch will retire, effective Oct 31. The company has appointed Robert McMahon, currently CFO of Hologic, as his successor. McMahon will join Agilent on Aug. 3 as senior VP and will become CFO on Sept. 1 when Hirsch steps down from that post. Hirsch will continue as an active member of the executive staff until his retirement date at the end of the fiscal year and will work with McMahon to ensure a smooth transition.

Hirsch has served as Agilent's CFO since 2010. Before that, he had oversight of the corporate controllership and tax functions. He joined Agilent in 1999 as VP of treasury and investor relations. He also held various international finance positions at HP from 1989 until joining Agilent.
McMahon has served as Hologic's CFO since 2014. Prior to that, he spent 20 years with Johnson & Johnson, most recently as worldwide VP of finance and business development for Ortho Clinical Diagnostics. He also held a variety of financial leadership positions within Johnson & Johnson after joining the company in 1993.

Separately, Hologic said it would promote its current Chief Accounting Officer Karleen Oberton to replace McMahon as CFO. She joined Hologic in 2006 as corporate controller and was promoted to her current position in 2015. Prior to that, Oberton served as senior corporate controller for Immunogen, and as a senior audit manager for both Ernst Young and Arthur Andersen.

Definiens has announced that it appointed Markus Schunk as COO, effective Sept. 15, 2018. Prior to Definiens, Schunk was CEO and board chairman at Holtzbrinck Digital. 

The companies will work on applying barcoding technology to single-cell measurements of gene and protein expression and to immune cell profiling.

Pacific Biosciences has appointed Christian Henry to its board of directors. Henry has served in executive level positions at Illumina for more than 10 years, including most recently as executive VP and chief commercial officer. Prior to joining Illumina, he served as CFO of Tickets.com and VP of finance at Affymetrix. He is also on the board at Ginkgo Bioworks and WAVE Life Sciences.

The firm is developing products based in part on DNA-enrichment and bioinformatics technologies developed at Stanford and Harvard, respectively.

Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.

Mark McDonough has been named chief business officer at diagnostics and bioinformatics firm Phosphorus. McDonough was previously president and CEO of CombiMatrix, now part of Invitae. He also held senior executive positions at Pathwork Dx and Laboratory Corporation of America. Phosphorus offers genetics testing in fertility, cardiology, lipidology, and other indications. It also offers the Elements software platform for labs to deploy the company's genetic tests on-premise as a local solution.

Natera has appointed Roy Baynes to its board of directors. Baynes is chief medical officer at Merck and senior vice president and head of global clinical development at Merck Research Laboratories. He has also held several roles at Gilead Sciences and Amgen and is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research. Prior to joining industry, Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute.

The company beat the consensus Wall Street estimate on the top line but missed it on the bottom line. It placed 39 net new ePlex analyzer during the quarter.